Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology.

Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, Roulois D, Turner J, Sylvestre M, Asam S, Glaysher B, Bowman SJ, Fearon DT, Filer A, Tarte K, Luther SA, Fisher BA, Buckley CD, Coles MC, Barone F.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13490-13497. doi: 10.1073/pnas.1905301116. Epub 2019 Jun 18.

2.

Distinct fibroblast subsets drive inflammation and damage in arthritis.

Croft AP, Campos J, Jansen K, Turner JD, Marshall J, Attar M, Savary L, Wehmeyer C, Naylor AJ, Kemble S, Begum J, Dürholz K, Perlman H, Barone F, McGettrick HM, Fearon DT, Wei K, Raychaudhuri S, Korsunsky I, Brenner MB, Coles M, Sansom SN, Filer A, Buckley CD.

Nature. 2019 Jun;570(7760):246-251. doi: 10.1038/s41586-019-1263-7. Epub 2019 May 29.

PMID:
31142839
3.

Perceptions of palliative care in a lower middle-income Muslim country: A qualitative study of health care professionals, bereaved families and communities.

Fearon D, Kane H, Aliou N, Sall A.

Palliat Med. 2019 Feb;33(2):241-249. doi: 10.1177/0269216318816275. Epub 2018 Dec 17. No abstract available.

4.

An unusual rash: Strongyloides stercoralis presenting as larva currens in a 12-year-old girl with Crohn's disease.

Wilson A, Fearon D.

J Paediatr Child Health. 2019 Mar;55(3):364-366. doi: 10.1111/jpc.14265. Epub 2018 Oct 13. No abstract available.

PMID:
30315617
5.

Paediatric Strongyloidiasis in Central Australia.

Wilson A, Fearon D.

Trop Med Infect Dis. 2018 Jun 13;3(2). pii: E64. doi: 10.3390/tropicalmed3020064.

6.

Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.

Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, Küttner V, Bružas E, Maiorino L, Bautista C, Carmona EM, Gimotty PA, Fearon DT, Chang K, Lyons SK, Pinkerton KE, Trotman LC, Goldberg MS, Yeh JT, Egeblad M.

Science. 2018 Sep 28;361(6409). pii: eaao4227. doi: 10.1126/science.aao4227.

PMID:
30262472
7.

Stromal Cells in the Tumor Microenvironment.

Denton AE, Roberts EW, Fearon DT.

Adv Exp Med Biol. 2018;1060:99-114. doi: 10.1007/978-3-319-78127-3_6. Review.

PMID:
30155624
8.

A philosophical critique of the UK's National Institute for Health and Care Excellence guideline 'Palliative care for adults: strong opioids for pain relief'.

Fearon D, Hughes S, Brearley SG.

Br J Pain. 2018 Aug;12(3):183-188. doi: 10.1177/2049463717753021. Epub 2018 Jan 10.

PMID:
30057763
9.

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases.

Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, Auffray C, Albrengues J, Egeblad M, Iacobuzio-Donahue CA, Lyons SK, Fearon DT.

Science. 2018 Jun 15;360(6394). pii: eaao4908. doi: 10.1126/science.aao4908. Epub 2018 May 17.

10.

Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.

Fearon D, Westwood IM, van Montfort RLM, Bayliss R, Jones K, Bavetsias V.

Bioorg Med Chem. 2018 Jul 15;26(11):3021-3029. doi: 10.1016/j.bmc.2018.04.033. Epub 2018 Apr 17.

11.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Review.

12.

The NICE-GUT trial protocol: a randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children.

Waddington CS, McLeod C, Morris P, Bowen A, Naunton M, Carapetis J, Grimwood K, Robins-Browne R, Kirkwood CD, Baird R, Green D, Andrews R, Fearon D, Francis J, Marsh JA, Snelling T.

BMJ Open. 2018 Feb 1;8(2):e019632. doi: 10.1136/bmjopen-2017-019632.

13.

Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, Wu D, Loughran RM, Emerling BM, Zhang G, Fearon DT, Cantley LC.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E743-E752. doi: 10.1073/pnas.1714703115. Epub 2018 Jan 8. Erratum in: Proc Natl Acad Sci U S A. 2018 Feb 20;:.

14.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD.

Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8.

15.

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11.

16.

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.

Connell CM, Raby S, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181. No abstract available.

17.

Connecting the Metabolic and Immune Responses to Cancer.

Flint TR, Fearon DT, Janowitz T.

Trends Mol Med. 2017 May;23(5):451-464. doi: 10.1016/j.molmed.2017.03.001. Epub 2017 Apr 7. Review.

PMID:
28396056
18.

Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities.

Fearon DT.

Cold Spring Harb Symp Quant Biol. 2016;81:219-226. doi: 10.1101/sqb.2016.81.030783. Epub 2017 Apr 7.

PMID:
28389597
19.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA.

J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

20.

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.

Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.

21.

Combination immunotherapy for cancer.

Fearon D.

J Exp Med. 2016 Jun 27;213(7):1115. doi: 10.1084/jem.2137insight2. No abstract available.

22.

Case 2: Diffuse Papulopustular Rash in an 11-week-old Boy.

Hogan A, Fearon D, Benedict FT.

Pediatr Rev. 2016 May;37(5):215-7. doi: 10.1542/pir.2015-0161. No abstract available.

PMID:
27139330
23.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

24.

T cell exclusion, immune privilege, and the tumor microenvironment.

Joyce JA, Fearon DT.

Science. 2015 Apr 3;348(6230):74-80. doi: 10.1126/science.aaa6204. Review.

PMID:
25838376
25.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

26.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.

Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.

27.

Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.

Dos Santos LI, Galvão-Filho B, de Faria PC, Junqueira C, Dutra MS, Teixeira SM, Rodrigues MM, Ritter G, Bannard O, Fearon DT, Antonelli LR, Gazzinelli RT.

Cancer Immunol Immunother. 2015 Mar;64(3):311-23. doi: 10.1007/s00262-014-1634-8. Epub 2014 Nov 18.

PMID:
25403749
28.

Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells.

Denton AE, Roberts EW, Linterman MA, Fearon DT.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12139-44. doi: 10.1073/pnas.1412910111. Epub 2014 Aug 4.

29.

Palliative care research in the francophone world.

Fearon D, Ahmedou AO.

BMJ Support Palliat Care. 2014 Sep;4(3):226-7. doi: 10.1136/bmjspcare-2014-000754. Epub 2014 Jul 22. No abstract available.

PMID:
25052303
30.

The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.

Fearon DT.

Cancer Immunol Res. 2014 Mar;2(3):187-93. doi: 10.1158/2326-6066.CIR-14-0002.

31.

Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Arnold JN, Magiera L, Kraman M, Fearon DT.

Cancer Immunol Res. 2014 Feb;2(2):121-6. doi: 10.1158/2326-6066.CIR-13-0150. Epub 2013 Nov 18.

32.

Private health care and empathy.

Fearon D.

Br J Gen Pract. 2014 Feb;64(619):90. doi: 10.3399/bjgp14X677185. No abstract available.

33.

Bite the bullet.

Fearon D.

J Epidemiol Community Health. 2014 Jun;68(6):585. doi: 10.1136/jech-2014-203806. Epub 2014 Feb 10. No abstract available.

PMID:
24516118
34.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

35.

Transcriptional regulation of effector and memory CD8+ T cell fates.

Thaventhiran JE, Fearon DT, Gattinoni L.

Curr Opin Immunol. 2013 Jun;25(3):321-8. doi: 10.1016/j.coi.2013.05.010. Epub 2013 Jun 6. Review.

36.

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia.

Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT.

J Exp Med. 2013 Jun 3;210(6):1137-51. doi: 10.1084/jem.20122344. Epub 2013 May 27.

37.

Tumour immunology.

Dranoff G, Fearon D.

Curr Opin Immunol. 2013 Apr;25(2):189-91. doi: 10.1016/j.coi.2013.02.012. Epub 2013 Mar 17. No abstract available.

38.

Control of HIV infection: escape from the shadow of Blimp-1.

Thaventhiran JE, Fearon DT.

Eur J Immunol. 2013 Feb;43(2):323-6. doi: 10.1002/eji.201243263.

39.

Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell.

Thaventhiran JE, Hoffmann A, Magiera L, de la Roche M, Lingel H, Brunner-Weinzierl M, Fearon DT.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):E2223-9. doi: 10.1073/pnas.1209115109. Epub 2012 Jun 27.

40.

siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFNA2 activation and IL-8 secretion.

Charlaftis N, Fearon DT, Schoenemeyer A, Morley PJ.

Biotechnol Appl Biochem. 2012 Jan-Feb;59(1):6-14. doi: 10.1002/bab.66. Epub 2012 Jan 23.

PMID:
22332739
41.

Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection.

Mackay LK, Wakim L, van Vliet CJ, Jones CM, Mueller SN, Bannard O, Fearon DT, Heath WR, Carbone FR.

J Immunol. 2012 Mar 1;188(5):2173-8. doi: 10.4049/jimmunol.1102719. Epub 2012 Jan 23.

42.

Protopathic stimulant use among children with symptoms of ADHD.

Barnard-Brak L, To YM, Fearon DD.

Atten Defic Hyperact Disord. 2011 Sep;3(3):245-51. doi: 10.1007/s12402-011-0055-1. Epub 2011 Mar 31.

PMID:
21452045
43.

T-bet-mediated differentiation of the activated CD8+ T cell.

Yeo CJ, Fearon DT.

Eur J Immunol. 2011 Jan;41(1):60-6. doi: 10.1002/eji.201040873. Epub 2010 Dec 9.

44.

Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection.

Bannard O, Kraman M, Fearon DT.

J Immunol. 2010 Dec 15;185(12):7141-5. doi: 10.4049/jimmunol.1002537. Epub 2010 Nov 10.

45.

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT.

Science. 2010 Nov 5;330(6005):827-30. doi: 10.1126/science.1195300.

46.

Coexisting disorders and academic achievement among children with ADHD.

Barnard-Brak L, Sulak TN, Fearon DD.

J Atten Disord. 2011 Aug;15(6):506-15. doi: 10.1177/1087054710369667. Epub 2010 Jun 7.

PMID:
20530458
47.
48.

Does pre-hospital telephone communication with a clinician result in more appropriate medication administration by parents during childhood asthma exacerbations?

Garro AC, Fearon D, Koinis-Mitchell D, McQuaid EL.

J Asthma. 2009 Nov;46(9):916-20. doi: 10.3109/02770900903229644.

PMID:
19905918
49.

The precursors of memory: models and controversies.

Ahmed R, Bevan MJ, Reiner SL, Fearon DT.

Nat Rev Immunol. 2009 Sep;9(9):662-8. doi: 10.1038/nri2619. Epub 2009 Aug 14. Review.

PMID:
19680250
50.

Pathways of memory CD8+ T-cell development.

Bannard O, Kraman M, Fearon D.

Eur J Immunol. 2009 Aug;39(8):2083-7. doi: 10.1002/eji.200939555. Review.

Supplemental Content

Loading ...
Support Center